Related Experiment Video
Updated: Feb 10, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Antidepressant-induced suicidality: how translational epidemiology incorporating pharmacogenetics into controlled
David Healy1, Kim Bechthold2, Peter Tolias3
1Department of Psychological Medicine, Cardiff University, Wales, UK.
Abstract:
Randomized controlled trials (RCTs) have been a staple of the drug development process for several decades. Here, we review the origins of RCTs and their adoption within drug development, highlighting shortcomings that tend to be ignored and possible solutions offered from personalized medicine. While RCTs play an important role in development of therapeutics, we underscore how if used indiscriminately, their adverse effects may outweigh the benefits. As an example, we focus on the development of antidepressants and how a severe adverse drug response - suicidal ideation - can be overlooked. We conclude with a discussion of how pharmacogenetics may address some of the deficiencies of RCTs, bringing the focus of drug response back to the individual patient rather than the population, using as an example the discovery of genetic markers associated with antidepressant-induced suicidal ideation.
Insights
Randomized controlled trials (RCTs) are crucial but can overlook severe adverse drug reactions like suicidal ideation. Personalized medicine, particularly pharmacogenetics, offers solutions by focusing on individual patient responses to improve drug development.
Area of Science:
- Pharmacology and Clinical Trials
- Personalized Medicine
- Drug Development
Background:
- Randomized controlled trials (RCTs) are a long-standing method in drug development.
- However, RCTs have limitations and potential adverse effects that are often overlooked.
- These shortcomings can impact patient safety and therapeutic efficacy.
Purpose of the Study:
- To review the history and adoption of RCTs in drug development.
- To highlight the limitations of RCTs, particularly in identifying severe adverse drug reactions.
- To explore how personalized medicine and pharmacogenetics can address these deficiencies.
Main Methods:
- Review of the origins and adoption of RCTs in therapeutic development.
- Analysis of shortcomings in RCT methodology.
- Case study focusing on antidepressant development and associated suicidal ideation.
- Discussion of pharmacogenetic approaches for personalized drug response prediction.
Main Results:
- RCTs, while valuable, can obscure individual patient responses and severe adverse events.
- The development of antidepressants illustrates how suicidal ideation can be overlooked in population-based trials.
- Pharmacogenetics shows promise in identifying genetic markers for predicting individual drug responses.
Conclusions:
- Indiscriminate use of RCTs may lead to adverse effects outweighing benefits.
- Pharmacogenetics can enhance drug development by personalizing drug response assessment.
- Focusing on individual genetic markers can improve patient safety and treatment outcomes.
Related Concept Videos
02:07Improving Translational Accuracy
02:07Improving Translational Accuracy
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:12Statistical Software for Data Analysis and Clinical Trials